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Calcimimetic NPS R-568 prevents parathyroid hyperplasia in perparathyroidism (HPT). Management of this acceler-
rats with severe secondary hyperparathyroidism. ated proliferative response is of critical importance in
Background. Secondary hyperparathyroidism (secondary preventing the adverse consequences to bone of sustainedHPT) in chronic renal insufficiency (CRI) is characterized by
elevations in the circulating levels of parathyroid hor-multiglandular hyperplasia.
mone (PTH) [1–6]. Several factors in which the levels areMethods. In this study, we investigated the effects of the
calcimimetic NPS R-568 on the parathyroid gland in rats with altered in CRI promote this hyperplasia. These include
CRI induced by ligation of the renal arteries and severe second- decreased circulating levels of 1,25-dihydroxyvitamin D3ary HPT induced by dietary phosphorus loading. Six days after [1,25(OH)2D3], hyperphosphatemia and hypocalcemia,surgery, high-phosphorus diet feeding was started, and NPS
as well as decreased expression in the parathyroid glandR-568 was administered to the rats for 56 days either by daily
of the receptors for 1,25(OH)2D3 and extracellular cal-gavage (30 or 100 mmol/kg) or by continuous subcutaneous
infusion (20 mmol/kg · day). cium [4, 7–16].
Results. After 54 days, serum PTH levels in vehicle-treated Because hypocalcemia is believed to be an important
CRI rats were 1019 vs. 104 pg/mL in sham-operated controls.
factor in the parathyroid hyperplasia in CRI, we investi-Infusion of NPS R-568 maintained serum PTH at levels compa-
gated the role of the calcium receptor in the parathyroidrable with those of sham-operated controls, whereas daily ga-
vage also prevented much of the increase in CRI controls cell proliferative response [17]. We used NPS R-568, an
and decreased PTH levels intermittently in a dose-dependent allosteric activator of the calcium receptor, which re-
fashion. Parathyroid gland enlargement was caused predomi- duces PTH secretion in vitro and in rats or patients with
nantly by hyperplasia. Total cell number per kg body wt was
primary or secondary HPT (abstract; Akizawa et al, J Am3.5-fold higher in vehicle-treated CRI rats than in sham-oper-
Soc Nephrol 19:561A,1998) [18–23]. We showed that theated controls. Both infusion and high-dose gavage of NPS
R-568 completely prevented the increase in parathyroid cell oral administration of NPS R-568 reduced serum PTH
number. levels and inhibited, in a dose-dependent fashion, the
Conclusion. These results demonstrate that the calcimimetic acute parathyroid cell proliferative response that oc-
compound NPS R-568 can prevent both the increase in serum
curred during the four days following a subtotal nephrec-PTH levels and parathyroid hyperplasia in rats with CRI and
tomy of rats fed normal rodent chow [17]. Thus, thatsevere secondary HPT. Moreover, these changes occurred de-
study was the first to link the calcium receptor to parathy-spite decreases in serum 1,25(OH)2D3 and increases in serum
phosphate, suggesting a dominant role for the calcium receptor roid cell proliferation. The experiment described in this
in regulating parathyroid cell proliferation. article extended that earlier observation to determine
whether the daily oral and/or sustained subcutaneous
administration of NPS R-568 for eight weeks would con-
Increased parathyroid cell proliferation (hyperplasia) tinue to inhibit parathyroid cell hyperplasia in uremic
is a common consequence of chronic renal insufficiency rats in which severe secondary HPT and hyperphospha-
(CRI) and results in the development of secondary hy- temia were induced by dietary phosphorus loading.
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Animals, surgery, and diets
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Male Sprague-Dawley rats (Crj: CD; Charles River,and in revised form July 20, 1999
Accepted for publication August 18, 1999 Tokyo, Japan) initially weighing 270 to 350 g were used
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Table 1. Experimental design planted subcutaneously. The rats were reanesthetized
on day 28, and the pumps were replaced. Treatment wasDose Dose
Group Status Treatment lmol/kg · day route continued for 56 days. Starting on day 4, blood samples
were collected once a week immediately before the daily1 Uremic Baseline — —
2 Sham Vehicle 0 p.o. gavage treatment for measurement of the circulating lev-
3 Uremic Vehicle 0 p.o. els of BUN, calcium, and phosphate. In addition, on days
4 Uremic NPS R-568 30 p.o.
11 and 54, blood samples were also collected for the5 Uremic NPS R-568 100 p.o.
6 Uremic NPS R-568 20 s.c. determination of serum PTH levels immediately before
and at one hour after dosing. Five rats died or wereNPS R-568 or vehicle (10% cyclodextrin) was administered by daily gavage
(orally) or continuously by an osmotic minipump (subcutaneous). euthanized during the study. Two animals from the infu-
sion group did not complete the study; one died under
anesthesia during pump replacement, and the second
was euthanized when the pump became exposed. Twodays, 48 rats were rendered uremic using a two-step
rats from the oral NPS R-568 groups (one high-dose andpartial ligation procedure. Animals were anesthetized
one low-dose) died as a result of gavaging accidents. Awith diethylether, and two branches of the left renal
second rat from the high-dose oral NPS R-568 groupartery were ligated. The right kidney was removed one died for unknown reasons. All data from these five ani-
week later. Sham operations were performed in nine mals were excluded from the final results.
rats. During the acclimation period and for six days after
removal of the right kidney, all rats received a commer- Parathyroid gland analysis
cial rodent diet (CE-2; CLEA Japan, Tokyo) containing Both parathyroid glands were removed from each rat
1.2% P, 1.1% Ca, 25% protein, and 2.5 I.U. vitamin by blunt dissection with the aid of a binocular dissecting
D3/g. The diet used for phosphorus loading contained microscope and were fixed overnight in cold (48C), neu-
1.2% P, 0.5% Ca, and 4 I.U. vitamin D3/g (Oriental Yeast tral phosphate-buffered formalin. The glands were dehy-
Co., Tokyo, Japan). Diets and tap water were provided drated in ethanol and embedded in JB-4 resin (Electron
ad libitum throughout the experiment. Microscopy Sciences, Fort Washington, PA, USA). Semi-
thin (3 mm) sections of both glands were prepared and
Experimental protocol stained with basic fuschin and methylene blue and were
Four days after the right nephrectomy and two days examined by light microscopy using oil immersion and
before the start of drug and diet treatment (day 22), phase contrast techniques.
Total gland volume, average cell volume, and totalthe rats were weighed, and blood samples were collected
cell number were determined using stereological tech-from the tail for measurement of serum levels of blood
niques [7, 24, 25]. The volume of each gland (VG) wasurea nitrogen (BUN), PTH, calcium, and phosphate.
estimated from parallel sections separated by a knownThree uremic rats with high BUN levels (.130 mg/dL)
distance t. The profile area [a(Prof.)] of each parallelwere eliminated from the study at this stage. The re-
section between interval sections was measured using amaining uremic rats were divided into five groups, each
digitizer. Thus, VG 5 t · S([a(Prof.)]. The total glandcontaining nine rats that were matched according to body
volume was determined by adding the volumes of theweight and the measured serum chemistries. At six days
paired glands.after the right nephrectomy (day 1), one group of uremic
The volume densities (volume per unit tissue volume)rats (baseline controls) were anesthetized with diethyl-
of epithelial cells and the volume densities of epithelialether and sacrificed by puncture of the abdominal aorta.
cell nuclei were estimated by point counting as describedBlood samples were collected for determination of the
previously [7, 25]. A total of eight test areas (100 3 100serum levels of BUN, creatinine, PTH, calcium, phos-
mm) was selected by random systematic subsamplingphate, and 1,25(OH)2D3. The parathyroid glands were from four random sections of each parathyroid gland
removed and processed for stereological analysis, as de- and were analyzed with a Nikon eyepiece containing 100
scribed later in this article. test points. The numerical density of epithelial cell nuclei
All remaining animals were transferred to the 1.2% was calculated assuming their shapes were spherical. To-
P, 0.5% Ca diet and were treated as described in Table tal parathyroid cell number (N) per rat was estimated
1. NPS R-568 was dissolved in 10% aqueous cyclodextrin from numerical density (NV) of cell nuclei in each gland
(2-hydroxypropyl-b-cyclodextrin; Research Biochemi- multiplied by the volume of each gland:
cals International, Natick, MA, USA) and administered
N 5 (NV1 3 VG1) 1 (NV2 3 VG2).by gavage at the same time each morning. For continuous
subcutaneous administration, one group of rats was anes-
Serum analysesthetized with diethylether, and a model 2ML4 osmotic
minipump (Alza, Palo Alto, CA, USA) containing NPS Serum PTH was measured using a homologous rat
PTH-(1-34) immunoradiometric assay (Immutopics, SanR-568 dissolved in 40% aqueous cyclodextrin was im-
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Clemente, CA, USA). Serum 1,25(OH)2D3 was mea-
sured by radioreceptor assay (Yamasa, Tokyo, Japan).
Serum creatinine was measured using an enzymatic
method (Kynos, Tokyo, Japan). BUN, total calcium, and
phosphate levels were measured using commercial kits
(Wako Pure Chemicals, Tokyo, Japan).
Statistical analysis
Only results from rats which completed the study and
from which both parathyroid glands were collected un-
damaged were included in the analyses (Statview; SAS
Institute, Cary, NC, USA). All data are expressed as
mean 6 se and were initially subjected to analysis of
variance. A repeated-measures analysis of variance was
used to analyze the time course studies. When F ratios
were significant, Fisher’s protected least significant dif-
ference multiple comparison test was used to determine
the significance of differences between groups. An un-
paired t-test was used for comparisons between sham
and CRI groups at baseline. A paired t-test was used to
compare serum PTH levels before and one hour after
drug administration. The correlation between serum pa-
rameters and parathyroid gland volume and cell number
and volume was analyzed using Pearson’s correlation
test.
RESULTS
Body weights and plasma analyses
Body weight was lower (332 6 5 vs. 385 6 11 g, P ,
0.001) in the CRI rats four days after surgery (day 22).
BUN levels were higher (69 6 3 vs. 28 6 1 mg/dL, P ,
0.001), and serum phosphate levels were lower (8.1 6
0.1 vs. 9.4 6 0.2 mg/dL, P , 0.001) in the CRI rats.
Neither serum calcium (9.9 6 0.1 vs. 10.1 6 0.1 Fig. 1. Effect of daily oral administration (30 or 100 mmol/kg) or contin-
mg/dL) nor PTH levels (19 6 2 vs. 28 6 3 pg/mL) were uous subcutaneous infusion (20 mmol/kg · day) of NPS R-568 for eight
weeks on serum levels of BUN, calcium, and phosphate in rats withsignificantly different at that time (Fig. 1).
chronic renal insufficiency (CRI) induced by a subtotal nephrectomyA substantial decrease in BUN levels to a nadir on on day 26. Treatment was initiated and the rats were given a high-
day 4 (10 days after surgery) occurred in all CRI rats. phosphorus diet starting on day 1. Values are mean 6 se (N 5 6 per
group). Missing sem bars are hidden within the symbols. Symbols are:Thereafter, BUN levels remained stable in the CRI rats
(s) sham operated, vehicle; (d —), chronic renal insufficiency (CRI),treated with NPS R-568 but tended to increase in the vehicle; (d - - -) CRI, R-568, 30 mmol/kg, oral; (n) CRI, R-568, 100
CRI rats that received vehicle, such that BUN levels mmol/kg, oral; (h) CRI, R-568, 20 mmol/kg, subcutaneous.
were significantly higher than in one or more NPS
R-568–treated groups from days 32 to 54 (Fig. 1). Serum
calcium levels decreased initially in sham-vehicle and
vehicle rats (Fig. 1). Phosphate levels increased in allCRI-vehicle rats when the 1.2% P, 0.5% Ca diet was
groups when the high-phosphorus diet was given. There-fed, although the magnitude of the decrease was greater
after, serum phosphate levels declined in the sham-vehiclein the uremic animals. Calcium levels tended to recover
group but remained elevated in the CRI-vehicle rats.in the sham-vehicle rats and to partially recover in the
Treatment of CRI rats with NPS R-568 had no significantCRI-vehicle rats but remained significantly lower in CRI
effect on serum phosphate levels at any time point. Apartthan in sham animals throughout the study. Serum cal-
from a transient increase in sham-vehicle rats on day 4,cium levels tended to be lower in CRI rats given the
there were no significant differences in serum calcium 3infusion or high-dose oral NPS R-568. However, the
phosphorus product throughout the study (Fig. 1).difference between CRI groups disappeared as the study
progressed because calcium levels declined in the CRI- Serum PTH levels prestudy and predose and one hour
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Fig. 2. Effect of daily oral administration (30 or 100 mmol/kg) or continuous subcutaneous infusion (20 mmol/kg · day) of NPS R-568 for eight
weeks on serum PTH levels in rats with CRI given a high phosphorus diet starting on day 1. To determine the acute effects of NPS R-568 on
PTH levels, blood samples were also collected before (pre-dose) and at one hour after dosing (post-dose) on treatment days 11 and 54. Values
are means 6 se (N 5 6 per group). aP , 0.05 vs. sham-vehicle and bP , 0.05 vs. CRI-vehicle groups. Symbols are: ( ) CRI, baseline; (h) sham,
vehicle; ( ) CRI, vehicle; ( ) CRI, 30 mmol/kg, oral; (j) CRI, 100 mmol/kg, oral; ( ) CRI, 20 mmol/kg, subcutaneous.
after dosing on days 11 and 54 are shown in Figure 2. CRI rats, and, like BUN, the magnitude of this increase
was blunted significantly in rats given NPS R-568. SerumThe high-phosphorus diet caused a progressive increase
in PTH levels in both sham-vehicle and CRI-vehicle rats, levels of 1,25(OH)2D3 were not reduced significantly in
vehicle-treated CRI rats. The administration of NPSbut the magnitude of the increase was considerably
greater (5.9 6 0.6-fold vs. 49 6 12-fold) in the uremic R-568 resulted in a dose-dependent decrease in 1,25-
(OH)2D3 levels, but the decrease was significant onlyanimals. The oral administration of NPS R-568 blunted
this increase in a dose-dependent fashion and the infu- when the compound was administered by continuous
infusion (Fig. 3).sion of NPS R-568 maintained serum PTH at the level
seen in the sham-vehicle group. The oral administration
Parathyroid gland histomorphometryof vehicle had no effect on PTH levels at one hour after
dosing in sham or CRI rats on days 11 and 54. In contrast, Parathyroid gland volume was 2.8-fold higher in vehi-
cle-treated CRI rats than in sham-operated rats at theNPS R-568 caused significant decreases in serum PTH
to levels not significantly different from those in sham- end of the study. This increase in gland volume was
caused by significant 1.2- and 2.5-fold increases in cellvehicle rats.
The effects on body weight gain during the eight-week volume and cell number, respectively. When normalized
to body weight, the increases in gland volume and cellstudy and serum creatinine and 1,25(OH)2D3 levels at
the end of the study are shown in Figure 3. Body weight number were even greater, averaging 3.9-and 3.5-fold,
respectively (Fig. 4). The oral administration of NPSgain was reduced significantly in CRI rats that received
vehicle. Although growth rate remained significantly R-568 for eight weeks suppressed the increase in gland
volume in a dose-dependent fashion. The average glandlower in CRI rats given NPS R-568, treated animals
tended to have higher growth rate, and the increase was volume in the 30 mmol/kg group was significantly lower
than in CRI-vehicle controls, but was still significantlysignificant when the compound was infused. Serum creat-
inine levels were significantly elevated in vehicle-treated higher than in the sham-vehicle group. However, both
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Fig. 4. Effect of daily oral administration (30 or 100 mmol/kg) or contin-
uous subcutaneous infusion (20 mmol/kg · day) of NPS R-568 for eightFig. 3. Effect of daily oral administration (30 or 100 mmol/kg) or contin-
weeks on total parathyroid gland volume, (A) average parathyroid celluous subcutaneous infusion (20 mmol/kg · day) of NPS R-568 for eight
volume, (B) and total parathyroid cell number (C ) in rats with CRIweeks on body weight gain (A) and serum creatinine (B) and 1,25(OH)2D3
given a high-phosphorus diet. To correct for increases caused by growthlevels (C ) in rats with CRI given a high-phosphorus diet. Values are
during the study, gland volume and cell number are shown normalizedmeans 6 se (N 5 6 per group). aP , 0.05 vs. sham-vehicle and bP ,
to body weight. Values are means 6 se (N 5 6 per group). aP , 0.050.05 vs. CRI-vehicle groups. Symbols are: ( ) CRI, baseline; (h) sham,
vs. sham-vehicle and bP , 0.05 vs. CRI-vehicle groups. Symbols are:vehicle; ( ) CRI, vehicle; ( ) CRI, 30 mmol/kg, oral; (j) CRI, 100
( ), CRI baseline; (h) sham, vehicle; ( ) CRI, vehicle; ( ) CRI, 30mmol/kg, oral; ( ) CRI, 20 mmol/kg, subcutaneous.
mmol/kg, oral; (j) CRI, 100 mmol/kg, oral; ( ) CRI, 20 mmol/kg,
subcutaneous.
the 100 mmol/kg oral dose and the infusion of NPS
R-568 maintained gland volume similar to that in sham- phate, and calcium levels. Treatment with NPS R-568
vehicle controls. The oral administration of NPS R-568 did not have a major effect on the correlation with PTH
prevented the increase in gland volume solely by pre- levels, but markedly reduced the correlations with phos-
venting cellular proliferation; cell volume was reduced phate and calcium levels. Parathyroid cell volume also
only in rats that received NPS R-568 by infusion (Fig. 4). correlated with PTH levels, but the correlations with
phosphate and calcium levels were weak and affected
Correlation analysis little by treatment with NPS R-568. Finally, the correla-
As expected, serum PTH levels were highly correlated tions between PTH, phosphate, and calcium levels with
with total parathyroid gland volume. The correlations total parathyroid cell number followed a pattern very
between gland volume and the serum levels of phosphate similar to that with parathyroid gland volume. No sig-
and calcium were weaker but remained highly significant. nificant correlations between 1,25(OH)2D3 levels and
In contrast, there was no correlation between gland vol- gland volume, cell volume, or cell number were observed
ume and 1,25(OH)2D3 levels (Fig. 5). A more detailed in either untreated or treated rats (Table 2).
analysis was made of the correlations between parathyroid
gland volume, cell volume, and cell number with serum
DISCUSSIONlevels of PTH, phosphate, calcium, and 1,25(OH)2D3 with
the effect of treatment with NPS R-568 analyzed sepa- We previously showed that the twice-daily oral admin-
istration of NPS R-568 (2 3 50 mmol/kg · day) for fourrately (Table 2). In untreated animals, parathyroid gland
volume was highly correlated with serum PTH, phos- days prevented the acute parathyroid cell proliferative
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largement. Moreover, a lower oral dose (30 mmol/kg)
was almost as effective at preventing the proliferative
response. This prevention occurred despite the much
greater stimulus to cellular hyperplasia that was induced
in the present study by feeding the animals a diet with
a high phosphorus-to-calcium ratio.
The goal of current therapies is to prevent parathyroid
hyperplasia and to reduce PTH levels by reversing the
changes in the circulating levels of calcium, phosphate,
and 1,25(OH)2D3 that occur in CRI. Calcium-containing
phosphate binders reduce the absorption of dietary phos-
phate, thereby decreasing plasma phosphate levels, and
increase the plasma levels of calcium. The administration
of 1,25(OH)2D3 also increases intestinal calcium absorp-
tion, but because it also promotes phosphate absorption,
control of hyperphosphatemia can be more difficult.
However, returning plasma phosphate levels to within
the normal range is not appropriate because the large
decrease in phosphate levels that occurs during the dial-
ysis procedure would result in severe hypophosphatemia
[26]. 1,25(OH)2D3 treatment is often associated with ele-
vations in plasma calcium levels above the upper limit
of normal. Together with the sustained hyperphosphate-
mia, this leads to a plasma calcium 3 phosphorus product
.70 mg2/dL2, a level at which metastatic calcification
occurs more frequently and which is associated with in-
creased morbidity and mortality [27, 28]. To help prevent
hypercalcemia, calcium-free phosphate binders and vita-
min D analogues with reduced calcemic activity have
been synthesized, which can lead to lower PTH levels
and lower incidences of hypercalcemic episodes [29–31].
Numerous clinical studies have shown that secondary
HPT and high bone turnover renal osteodystrophy are
common occurrences long before kidney function has
declined to a level at which dialysis becomes necessary
[32, 33]. Although efforts to prevent the development
of 28HPT in predialysis patients have been made, the
most aggressive treatment is usually reserved until after
the patient has begun dialysis [33–35]. For example, con-
cerns have been raised that the use of vitamin D ana-
logues and calcium-containing phosphate binders will
elevate circulating calcium and/or phosphate levels,
Fig. 5. Analysis of the correlations between serum levels of PTH (A), which might accelerate the progression to end-stage re-
phosphate (B), calcium (C ), and 1,25(OH)2D3 (D) with total parathyroid nal disease [27, 28, 36]. These studies in rats have showngland volume in sham-operated and CRI rats that received vehicle (s)
that the administration of NPS R-568 prevents the devel-and in CRI rats that received NPS R-568 (d).
opment of secondary HPT and achieves this without
causing hypercalcemia or significant hyperphosphate-
mia. The tendency toward an increase in serum phos-
response that occurred following a subtotal nephrectomy phate levels in rats treated with NPS R-568 (an expected
of rats fed normal rodent chow [17]. In the current exper- consequence of reduced PTH activity in the remnant
iments, we extended those findings to show that once kidney and reduced phosphaturia) was offset by the de-
daily administration of the same total oral dose (100 crease in serum calcium levels such that the serum cal-
mmol/kg) or a sustained subcutaneous infusion of NPS cium 3 phosphorus product was unchanged throughout
R-568 for eight weeks continued to prevent the develop- the study.
Treatment with NPS R-568, either by daily oral gavagement of parathyroid cell hyperplasia and glandular en-
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Table 2. Correlation analysis of parathyroid gland volume, average parathyroid cell volume, and total parathyroid cell number versus
serum levels of PTH, phosphate, calcium, and 1,25(OH)2D3
Gland volume Cell volume Cell number
Untreated Treated Total Untreated Treated Total Untreated Treated Total
PTH 0.957 0.841 0.928 0.583 0.571 0.463 0.831 0.734 0.893
(,0.001) (,0.001) (,0.001) (0.045) (0.012) (0.009) (,0.001) (,0.001) (,0.001)
Calcium 20.851 20.539 20.494 20.500 20.348 20.390 20.845 20.495 20.480
(,0.001) (0.020) (0.005) (NS) (NS) (0.034) (,0.001) (0.036) (0.007)
Phosphate 0.839 0.595 0.533 0.408 0.453 0.431 0.831 0.519 0.502
(,0.001) (0.008) (0.002) (NS) (NS) (0.017) (,0.001) (0.026) (0.004)
1,25(OH)2D3 20.224 20.188 20.045 0.033 20.061 20.049 20.205 20.208 20.049
(NS) (NS) (NS) (NS) (NS) (NS) (NS) (NS) (NS)
N 12 18 30 12 18 30 12 18 30
Shown are the correlation coefficients for each analysis with the corresponding P value in parentheses; NS is nonsignificant. Gland volume and cell number per
kg were used in the analyses. Untreated animals include both sham-operated and CRI rats that received vehicle. Treated animals were all CRI rats that received
NPS R-568 by oral or s.c. routes.
or by sustained subcutaneous infusion, was associated administration of 1,25(OH)2D3 to uremic animals inhib-
ited parathyroid cell proliferation [7]. Our studies sug-with a prevention of a modest, but progressive, increase
in circulating BUN and creatinine levels. The reduction gest that the inhibition of hyperplasia was secondary to
the induced elevation in serum calcium levels and mayin BUN and creatinine levels was not caused by reduced
food intake and body weight because animals treated not be a direct effect of 1,25(OH)2D3 itself on the para-
thyroid gland. The administration of 1,25(OH)2D3 in thewith NPS R-568 gained more weight than vehicle-treated
CRI controls. We have previously observed a lower cir- study of Szabo et al was also associated with an increase
in serum phosphate levels [7]. Slatopolsky et al haveculating creatinine level in other long-term studies in
CRI rats given NPS R-568 [21]. Thus, these data suggest long proposed that hyperphosphatemia in CRI is the
major driving force for parathyroid cell hyperplasia [1,that treatment with calcimimetics like NPS R-568 will
prevent the development of secondary HPT and may 8, 9, 39]; our results from untreated animals in this study
and in others [20] support this concept. However, thealso retard the progression toward end-stage renal dis-
ease. Confirmation of this latter hypothesis will, how- inhibition of cellular hyperplasia following 1,25(OH)2D3
administration in the study of Szabo et al was associatedever, require large scale studies of longer duration in
which the glomerular filtration rate is measured repeat- with an increase in both serum calcium and phosphate
levels [7]. This suggests that elevated serum calcium lev-edly.
This study also provided some insights into the mecha- els can overwhelm any hyperplastic effects of high serum
phosphate. Our data from rats treated with the calcimi-nisms responsible for parathyroid gland enlargement in
severe secondary HPT. Although increased average cell metic NPS R-568 support this hypothesis. The daily oral
administration or sustained infusion of NPS R-568 involume (hypertrophy) played a role, the increased cell
number (hyperplasia) was by far the major contributor. both this experiment and our earlier short-term study
[17] was able to prevent parathyroid cell hyperplasiaThe driving force behind increased cell volume is un-
clear. Although significant correlations existed between completely, despite a modest increase in serum phos-
phate. We have also shown that NPS R-568 administra-cell volume and the serum levels of phosphate and cal-
cium, the correlations were relatively weak. In contrast, tion reduces plasma PTH by an equivalent amount in
CRI rats with plasma phosphate levels that vary fromcorrelation analysis suggested that both high serum phos-
phate and low serum calcium levels contributed to the normal to four times normal, confirming the dominant
role of the calcium receptor in regulating PTH secretionhyperplasia. However, there were no correlations be-
tween parathyroid gland volume or cell number and cir- in vivo [20].
The oral administration of NPS R-568 also results inculating 1,25(OH)2D3 levels. This lack of correlation oc-
curred despite the tendency for dose-dependent a transient decrease in the circulating levels of calcium
[19, 20]. The observation that parathyroid cell hyperpla-decreases in 1,25(OH)2D3 levels following NPS R-568
administration. The decrease in 1,25(OH)2D3 levels is sia is inhibited in CRI rats treated with NPS R-568,
despite the fall in serum calcium levels, supports thepresumably a consequence of the induced decrease in
serum PTH and increase in phosphate levels, although concept that the calcium receptor is mediating the hyper-
plasia. If the glands responded to the prevailing lowwe cannot exclude the possibility of a direct inhibitory
effect of NPS R-568 on 1,25(OH)2D3 synthesis that is circulating calcium levels by a mechanism other than via
the calcium receptor, an enhanced proliferative responsemediated by calcium receptors in the proximal tubule
[37, 38]. Earlier studies by Szabo et al showed that the would be expected. We anticipate that the induced fall
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